Brian Bonfardin
Psychiatry · Johnson City, TNNPI 1356322515
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,296,822 of the $2,627,589 with a category attached, or 87.4%. 22 manufacturers reported payments, led by AbbVie at 30.5% of the total. 2025 is the largest year on record at $768,585, 5.2 times the $148,934 reported in 2019. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,123 payments — averaging $841.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$802K
- Otsuka America Pharmaceutical, Inc.$489K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$481K
- Vanda Pharmaceuticals Inc.$368K
- Axsome Therapeutics, Inc.$177K
- Supernus Pharmaceuticals, Inc.$122K
- plus $188K from 16 others
What the payments were for
- Consulting fees$98,2254%
- Speaking & faculty fees$2,296,82287%
- Travel & lodging$186,6227%
- Food & beverage$45,7122%
- Education$2080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 892 | $801,951 |
| Otsuka America Pharmaceutical, Inc. | 541 | $489,136 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 441 | $481,177 |
| Vanda Pharmaceuticals Inc. | 465 | $368,028 |
| Axsome Therapeutics, Inc. | 174 | $177,157 |
| Supernus Pharmaceuticals, Inc. | 214 | $122,312 |
| Alkermes, Inc. | 151 | $114,562 |
| Takeda Pharmaceuticals U.S.A., Inc. | 102 | $39,849 |
| E.r. Squibb & Sons, L.L.C. | 38 | $28,446 |
| Johnson & Johnson | 16 | $2,212 |
| Sunovion Pharmaceuticals Inc. | 49 | $2,007 |
| Teva Pharmaceuticals USA, Inc. | 14 | $375 |
| Lundbeck LLC | 11 | $155 |
| Neurocrine Biosciences, Inc. | 4 | $64 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $14 |
| Neuronetics, Inc. | 1 | $14 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$772,518
- CAPLYTA$475,533
- LYBALVI$446,027
- Fanapt$361,742
- REXULTI$277,683
- ABILIFY MAINTENA$206,373
- Auvelity$175,062
- QELBREE$116,188
- ABILIFY ASIMTUFII$113,543
- TRINTELLIX$24,395
- COBENFY$16,681
- VYVANSE$13,998
- SPRAVATO$1,950
- LATUDA$1,505
How this compares
$2,627,589 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 66 | $188,521 |
| CaplytaLumateperone Tosylate | 12 | $47,075 |
| RexultiBrexpiprazole | 19 | $40,955 |
| VraylarCariprazine Hcl | 17 | $23,739 |
| Asenapine Maleate | 29 | $15,532 |
| TrintellixVortioxetine Hydrobromide | 29 | $14,028 |
| Lamotrigine ErLamotrigine | 28 | $12,122 |
| Aripiprazole | 90 | $4,140 |
| Oxcarbazepine | 37 | $3,046 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $2,390 |
| Lurasidone Hcl | 19 | $2,347 |
| Carbamazepine ErCarbamazepine | 12 | $1,958 |
| Duloxetine Hcl | 70 | $1,420 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 16 | $1,080 |
| Clonazepam | 112 | $923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $368,028 | $188,52166 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $481,177 | $47,07512 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $489,136 | $40,95519 claims |
| AbbVieVraylar | $801,951 | $23,73917 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $39,849 | $14,02829 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $61257 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Johnson City
- John FenleyJohnson City$1.4M
- George BrownJohnson City$91K
- Kevin TurnerJohnson City$9K
- Rakesh AminNashville$3M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- Sricharan MoturiFranklin$82K
- Michelle CochranNashville$74K
- Daniel BoydMemphis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.